Description |
A cell-permeable, reversible, and ATP-competitive Ca2+ antagonist with anti-vasospastic properties. Inhibits protein kinase A (Ki = 1.6 µ M), protein kinase G (Ki = 1.6 µ M), and myosin light chain kinase (Ki = 3.6 µ M). Also reported to potently inhibit Rho-associated kinase (ROCK, IC50 = 10.7 µ M). Prevents apoptosis and enhances the survival and cloning efficiency of dissociated hES cells without affecting their pluripotency. |
Reference |
1. Watanabe, K. et al. Nature Biotech. 2007, 25, 681
2. Swärd, K. et al. J. Physiol. 2000, 522, 33
3. Takizawa, S. et al. Eur. J. Pharmacol. 1993, 250, 431
4. Seto, M. et al. Eur. J. Pharmacol. 1991, 195, 267
5. Shirotani, M. et al. J. Pharmacol. Exp. Ther. 1991, 259, 738
6. Asano, T. et al. Eur. J. Pharmacol. 1990, 190, 365
7. Sasaki, Y., and Sasaki, Y. Biochem. Biophys. Res. Commun. 1990, 171, 1182
8. Asano, T. et al. Br. J. Pharmacol. 1989, 98, 1091. |